ArticleCancers2020
Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 5 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Efficacy of Mobile App-Based Dietary Interventions Among Cancer Survivors: Systematic Review and Meta-Analysis.JMIR mHealth and uHealth · 2025Pooled it
- The prognostic value of sarcopenia in oesophageal cancer: A systematic review and meta-analysis.Journal of cachexia, sarcopenia and muscle · 2023Pooled it
- Skeletal Muscle Change During Neoadjuvant Therapy and Its Impact on Prognosis in Patients With Gastrointestinal Cancers: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Computed tomography-defined low skeletal muscle index and density in cancer patients: observations from a systematic review.Journal of cachexia, sarcopenia and muscle · 2021Pooled it
- The Impact of Preoperative Sarcopenia on Survival Prognosis in Patients Receiving Neoadjuvant Therapy for Esophageal Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Goal-directed nutritional support in preserving muscle mass and optimising recovery in treatment of oesophageal cancer: results of a prospective non-randomised cluster trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Trial
- Prognostic Significance of the T12-SMI Before and After Neoadjuvant Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma.Annals of surgical oncology · 2026Article
- Impact of Muscle Mass Loss on Survival During Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-center Retrospective Study in China (TIMES Study).Annals of surgical oncology · 2026Article
- Computed Tomography-Based Assessment of Sarcopenia and Disease Progression in Pancreatic Ductal Adenocarcinoma: A Radiomics and Machine Learning Approach.Gastroenterology research · 2026Article
- Sarcopenia in esophageal cancer: from passive prognostic marker to active treatment target.Journal of gastrointestinal oncology · 2026Article
- Article
- Article
- Association of sarcopenia with pathologic complete response in esophageal squamous cell carcinoma patients undergoing neoadjuvant immunochemotherapy.BMC cancer · 2026Article
- Development and validation of a machine learning-based risk prediction model for sarcopenia in community hospital patients: a retrospective cohort study.Frontiers in aging · 2026Article
- Skeletal muscle volume by 3D imaging and long-term survival in esophageal squamous cell carcinoma with neoadjuvant chemotherapy.General thoracic and cardiovascular surgery · 2026Article
- L3-SMI as a predictor of overall survival in oesophageal cancer patients receiving PD-1 inhibitors combined with chemotherapy.Annals of medicine · 2025Article
- Effects of nutritional support during neoadjuvant therapy on perioperative outcome in esophageal cancer: a real-world cohort study.Journal of thoracic disease · 2025Article
- Sarcopenia following concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.Journal of gastrointestinal oncology · 2025Article
- Prognostic Impact of Sarcopenia and Surgical Timing in Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Chemoradiotherapy: TIMES Study.Annals of surgical oncology · 2025Article
- Sarcopenic psoas muscle surface area predicts short and long-term mortality for oesophageal cancer patients.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsThe relationship between sarcopenia, characterized by loss of muscle mass and strength, and survival outcomes of esophageal cancer is controversial. This study aimed to assess the effect of sarcopenia and skeletal muscle loss on overall survival (OS) and recurrence-free survival (RFS) of esophageal cancer patients.
methodsWe retrospectively collected the medical records of 248 male patients diagnosed with squamous cell esophageal cancer and who underwent neoadjuvant chemoradiotherapy (NACRT) followed by surgery. We measured the cross-sectional area of the skeletal muscle at the L3 vertebra level using computed tomography images and calculated the skeletal muscle index (SMI). Sarcopenia was defined as SMI <52.4 cm
resultsIn the univariable Cox analysis, pre- (
conclusionExcessive muscle loss rather than pre- and post-RT sarcopenia was a significant prognostic factor for OS and RFS, and it was also related to nutritional and inflammatory markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.